All In Biotech

Drugs by condition

Drugs approved for myasthenia gravis

Brand-name prescription drugs and biologics whose FDA label lists myasthenia gravis as an approved use. Matched on the label phrases: "myasthenia gravis".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

13

Still marketed, NDA or BLA

Drug classes

5

Novel drugs

8

New molecular entities and new biologics

In development

15

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for myasthenia gravis.

  • Imaavy (Nipocalimab-Aahu) · Janssen Biotech NovelPriority reviewOrphanApr 29, 2025
  • Epysqli (Eculizumab-Aagh) · Samsung Bioepis CO LTD Jul 19, 2024
  • Bkemv (Eculizumab-Aeeb) · Amgen INC May 28, 2024
  • Rystiggo (Rozanolixizumab-Noli) · Ucb INC NovelPriority reviewOrphanJun 26, 2023
  • Vyvgart Hytrulo (Efgartigimod Alfa and Hyaluronidase-Qvfc) · Argenx Bv Priority reviewOrphanJun 20, 2023

All approved drugs for myasthenia gravis, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 10 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Complement Inhibitor (4)

  • Ultomiris Ravulizumab-Cwvz · Alexion Pharm · 2018
  • Soliris Eculizumab · Alexion Pharm · 2007
  • Epysqli Eculizumab-Aagh · Samsung Bioepis CO LTD · 2024
  • Bkemv Eculizumab-Aeeb · Amgen INC · 2024

Neonatal Fc Receptor Blocker (2)

  • Rystiggo Rozanolixizumab-Noli · Ucb INC · 2023
  • Vyvgart Efgartigimod Alfa · Argenx Bv · 2021

CD19-directed Cytolytic Antibody (1)

  • Uplizna Inebilizumab-Cdon · Viela Bio · 2020

Endoglycosidase (1)

  • Vyvgart Hytrulo Efgartigimod Alfa and Hyaluronidase-Qvfc · Argenx Bv · 2023

Class not listed in FDA's data (5)

  • Imaavy Nipocalimab-Aahu · Janssen Biotech · 2025
  • Protopam Chloride Pralidoxime Chloride · Baxter Hlthcare Corp · 1964
  • Mestinon Pyridostigmine Bromide · Bausch · 1955
  • Mestinon Pyridostigmine Bromide · Bausch · 1965
  • Mestinon Pyridostigmine Bromide · Bausch · 1959

Drugs in development for myasthenia gravis

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • EmpasiprubartARGX-117Phase 39 trials

    argenx · Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy, CIDP

  • FelzartamabPhase 38 trials

    Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease

  • TelitaciceptRC18, RC18-LPhase 38 trials

    RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease

  • IMVT-1402Phase 37 trials

    Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus

  • PovetaciceptALPN-303Phase 37 trials

    Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy

  • CemdisiranALN-CC5Phase 35 trials

    Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)

  • ClaseprubartDNTH103Phase 34 trials

    Dianthus Therapeutics · Myasthenia Gravis, Generalized, Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy

  • Rese-celCABA-201Phase 34 trials

    Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma

  • B007Phase 33 trials

    Shanghai Jiaolian Drug Research and Development Co., Ltd · Pemphigus, Primary Membranous Nephropathy, Generalized Myasthenia Gravis

  • KYV-101Phase 32 trials

    Kyverna Therapeutics · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis

  • SHR-2173Phase 25 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy

  • Descartes-08Phase 24 trials

    Cartesian Therapeutics · Myasthenia Gravis, Generalized, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)

  • NMD670Phase 23 trials

    NMD Pharma A/S · Myasthenia Gravis, Myasthenia Gravis, MuSK, Charcot-Marie-Tooth Disease

  • AritinerceptPhase 21 trial

    Aurinia Pharmaceuticals Inc. · Myasthenia Gravis, Generalized

  • CNP-106Phase 21 trial

    COUR Pharmaceutical Development Company, Inc. · Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis

More on myasthenia gravis: recruiting trials · published research

Related in neurology: Alzheimer's disease · Parkinson's disease · Multiple sclerosis · Epilepsy and seizures · Migraine · ALS (amyotrophic lateral sclerosis) · Spinal muscular atrophy · Duchenne muscular dystrophy · Huntington's disease chorea · Tardive dyskinesia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.